A 53-year old man, diabetic, with an unresectable endocrine pancreatic carcinoma was diagnosed with additional abdominal metastases as documented by CT and biopsy. In August 2007, scintigraphic images with octreoscan demonstrated high uptake in the abdominal lesions. [Figure 1A](#f1-can-2-106){ref-type="fig"} shows the trans-axial and coronal slices of fused SPECT-CT, with uptake in the abdominal lesion (red arrow), kidneys and spleen. In November 2007, the patient underwent the first cycle of receptor peptide radionuclide therapy with 1.7 GBq of ^90^Y-DOTATATE.

Post-therapy SPECT-CT ^90^Y-Bremsstrahlung images were acquired at 24 and 48 hours, with the same settings, excluding energy windows, as for octreoscan. The hybrid system Siemens Symbia T2 was used for SPECT acquisition, with medium energy collimators, 80 (50%) and 120 (30%) keV energy windows, 128 × 128 matrix, 64 projections (40 s/step). Low-dose CT was acquired (80 mAs) and used for attenuation correction. Images were reconstructed with the OSEM 3D Fast algorithm with automatic correction for 3D response of the collimator.

The ^90^Y-Bremsstrahlung images obtained give more detailed information on biodistribution, in comparison to the ^111^In-diagnostic images, which are more suitable for tumour and normal organ dosimetry. [Figure 1B](#f1-can-2-106){ref-type="fig"} shows the corresponding trans-axial and coronal slices of fused SPECT-CT as with octreoscan. Increased uptake in the abdominal lesion (red arrow) and higher uptake in the renal cortex than the medulla (yellow arrow) \[[@b1-can-2-106]\] can be clearly distinguished. This is consistent with the different distribution of DOTATATE versus octreoscan.

The higher quality of the Bremsstrahlung images means that the diagnostic examination can be aimed at patient recruitment (suitability or not for treatment) and so restricting dosimetry evaluation only to treated patients. This could avoid the need for a tracer to mimic therapy and overcome difficulties of ^86^Y quantification \[[@b2-can-2-106]\]. The clinical impact might be notable as dosimetry and toxicity information are essential in radionuclide therapy especially in patients with associated risk factors (e.g. diabetes) \[[@b3-can-2-106]\].
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